Theravance Biopharma完成关键性3期Cypress研究入组,该研究评估安普洛西汀治疗多系统萎缩引起的症状性神经源性直立性低血压

美股速递
Aug 25, 2025

Theravance Biopharma已完成其关键性3期Cypress研究的患者入组工作。该研究旨在评估安普洛西汀在治疗由多系统萎缩引起的症状性神经源性直立性低血压患者中的疗效。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10